These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 15991882)

  • 1. BG 12: BG 00012, BG 12/Oral Fumarate, FAG-201, second-generation fumarate derivative--Fumapharm/Biogen Idec.
    Drugs R D; 2005; 6(4):229-30. PubMed ID: 15991882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug evaluation: BG-12, an immunomodulatory dimethylfumarate.
    Wakkee M; Thio HB
    Curr Opin Investig Drugs; 2007 Nov; 8(11):955-62. PubMed ID: 17979030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of fumaric acid esters in psoriasis.
    Roll A; Reich K; Boer A
    Indian J Dermatol Venereol Leprol; 2007; 73(2):133-7. PubMed ID: 17456929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a review of clinical data.
    Landeck L; Asadullah K; Amasuno A; Pau-Charles I; Mrowietz U
    Arch Dermatol Res; 2018 Aug; 310(6):475-483. PubMed ID: 29574575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody.
    Drugs R D; 2004; 5(2):102-7. PubMed ID: 15293871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the biomedical applications of fumaric acid and its ester derivatives: The multifaceted alternative therapeutics.
    Das RK; Brar SK; Verma M
    Pharmacol Rep; 2016 Apr; 68(2):404-14. PubMed ID: 26922546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Organising pneumonia associated with fumaric acid ester treatment for psoriasis.
    Deegan AP; Kirby B; Rogers S; Crotty TB; McDonnell TJ
    Clin Respir J; 2010 Oct; 4(4):248-51. PubMed ID: 20887349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
    Gold R; Kappos L; Arnold DL; Bar-Or A; Giovannoni G; Selmaj K; Tornatore C; Sweetser MT; Yang M; Sheikh SI; Dawson KT;
    N Engl J Med; 2012 Sep; 367(12):1098-107. PubMed ID: 22992073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dimethyl fumarate for multiple sclerosis.
    Papadopoulou A; D'Souza M; Kappos L; Yaldizli O
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1603-12. PubMed ID: 21067468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
    Fox RJ; Miller DH; Phillips JT; Hutchinson M; Havrdova E; Kita M; Yang M; Raghupathi K; Novas M; Sweetser MT; Viglietta V; Dawson KT;
    N Engl J Med; 2012 Sep; 367(12):1087-97. PubMed ID: 22992072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dimethyl fumarate for treating relapsing multiple sclerosis.
    Sheremata W; Brown AD; Rammohan KW
    Expert Opin Drug Saf; 2015 Jan; 14(1):161-70. PubMed ID: 25382392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus.
    Mrowietz U; Barker J; Boehncke WH; Iversen L; Kirby B; Naldi L; Reich K; Tanew A; van de Kerkhof PCM; Warren RB
    J Eur Acad Dermatol Venereol; 2018 Oct; 32 Suppl 3():3-14. PubMed ID: 30238510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies.
    Linker RA; Lee DH; Stangel M; Gold R
    Expert Rev Neurother; 2008 Nov; 8(11):1683-90. PubMed ID: 18986239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dimethylfumarate for psoriasis: Pronounced effects on lesional T-cell subsets, epidermal proliferation and differentiation, but not on natural killer T cells in immunohistochemical study.
    Bovenschen HJ; Langewouters AM; van de Kerkhof PC
    Am J Clin Dermatol; 2010; 11(5):343-50. PubMed ID: 20553063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and safety profile of fumaric acid esters in oral long-term therapy with severe treatment refractory psoriasis vulgaris. A study of 83 patients].
    Altmeyer P; Hartwig R; Matthes U
    Hautarzt; 1996 Mar; 47(3):190-6. PubMed ID: 8647701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm
    Mrowietz U; Szepietowski JC; Loewe R; van de Kerkhof P; Lamarca R; Ocker WG; Tebbs VM; Pau-Charles I
    Br J Dermatol; 2017 Mar; 176(3):615-623. PubMed ID: 27515097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fumaric acid and its derivatives in the treatment of psoriasis vulgaris: our experience in forty-one patients.
    Kokelj F; Plozzer C; Avian A; Trevisan G
    Acta Dermatovenerol Croat; 2009; 17(3):170-5. PubMed ID: 19818215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fumaric acid and its esters in the treatment of multiple sclerosis: studies and effects].
    Stangel M; Moharregh-Khiabani D; Linker RA; Gold R
    Nervenarzt; 2008 Feb; 79(2):212-7. PubMed ID: 18210050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mode of action and clinical studies with fumarates in multiple sclerosis.
    Salmen A; Gold R
    Exp Neurol; 2014 Dec; 262 Pt A():52-6. PubMed ID: 24568735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Fumaric acid therapy in psoriasis; a double-blind, placebo-controlled study].
    Nugteren-Huying WM; van der Schroeff JG; Hermans J; Suurmond D
    Ned Tijdschr Geneeskd; 1990 Dec; 134(49):2387-91. PubMed ID: 2263264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.